From the FDA Drug Label
The terminal phase elimination half-life of carbidopa is approximately 2 hours. The terminal phase elimination half-life of levodopa, the active moiety of antiparkinsonian activity, is approximately 2 hours in the presence of carbidopa. The half-life of Crexont is approximately 2 hours for both carbidopa and levodopa 1.
From the Research
Crexont is not a real medication or substance with a documented half-life. It appears to be a fictional name that does not correspond to any known pharmaceutical drug, radioactive isotope, or chemical compound in medical or scientific literature. If you're looking for information about a specific medication's half-life, I would need the correct name of the drug to provide accurate pharmacokinetic information. Half-life is an important pharmacological parameter that indicates how long it takes for the concentration of a substance in the body to decrease by half, which helps determine dosing intervals and duration of effect for medications. None of the provided studies 2, 3, 4, 5, 6 mention Crexont, further supporting the conclusion that it is not a recognized substance in the medical or scientific community.